Evaluation of free-radical quenching properties of standard Ayurvedic formulation Vayasthapana Rasayana

<p>Abstract</p> <p>Background</p> <p>Cellular damage induced by free-radicals like Reactive Oxygen and Nitrogen Species (ROS and RNS) has been implicated in several disorders and diseases, including ageing. Hence naturally occurring anti-oxidant rich-herbs play a vital role in combating these conditions. The present study was carried out to investigate the <it>in vitro </it>free-radical quenching capacity of a known <it>Ayurvedic </it>poly-herbal formulation called <it>Vayasthapana Rasayana.</it></p> <p>Methods</p> <p>Methanol extracts of <it>Vayasthapana Rasayana </it>formulation (VRF) were studied for <it>in vitro </it>total antioxidant activity along with phenolic content and reducing power. <it>In vitro </it>assays like DPPH, FRAP, ABTS scavenging to evaluate radical quenching potential were performed.</p> <p>Results</p> <p>The formulation has shown 94% at 0.1 mg/ml DPPH free-radical scavenging activity as against 84% at 0.1 mg/ml for standard ascorbic acid (IC₅₀value 5.51 μg/ml for VRF and 39 μg/ml for standard). It has a significant higher ferric reducing potential also (OD 0.87 at 700 nm & 0.21 at 0.1 mg/ml for VRF and standard, respectively). The total phenolic content (gallic acid equivalent) of the VRF is 8.3 mg per g of dry mass. Total antioxidant capacity of the formulation, estimated by FRAP was 1150 ± 5 μM Fe(II)/g dry mass. ABTS radical scavenging activity of VRF was 69.55 ± 0.21% at 100 μg/ml concentration with a IC₅₀value of 69.87 μg/ml as against 9% and 95% by ascorbic acid and Trolox (at 70.452 μg/ml and 0.250 μg/ml concentrations, respectively).</p> <p>Conclusion</p> <p>In Indian traditional <it>Ayurvedic </it>system, use of VRF is in regular practice for mainly combating age-related disorders and diseases as many of the components of the <it>Rasayana </it>are known for their free-radical scavenging activity. This study has validated the potential use of VRF as an anti-oxidant to fight age-related problems.</p

Effect of new polyherbal formulations DF1911, DF2112 and DF2813 on CFA induced inflammation in rat model

Abstract Background Aim of the present study was to evaluate anti-inflammatory activity of newly developed polyherbal formulations DF1911, DF2112 and DF2813. These newly developed formulations are modifications of Dashamoola, a well known Ayurvedic formulation, along with addition of new plants. Methods Complete Freund’s adjuvant (CFA) induced inflammation in rat was used as an experimental model. Effects of the treatment in rats were monitored by physiological and biochemical parameters, histopathology and through gene expression studies. Results Diclofenac sodium showed maximum percentage inhibition (56.8 ± 3.5%) of paw edema followed by Dashamoola Kwatha (19.9 ± 1.8%). Among test formulations treated groups, DF1911 at 250 mg/kg bw (48.2 ± 5.4%, p < 0.001) and DF2112 at 250 mg/kg bw (49.9 ± 3.5%, p < 0.001) showed significant and maximum increase in percentage inhibition of paw edema as compared to Dashamoola Kwatha. Hematological alterations in CFA rats were normalized after treatment with test formulations. Results of serum markers and histopathological observations also supported the activity of formulations. Increased MDA levels in liver tissue of CFA injected animals significantly (p < 0.05) decreased by Diclofenac sodium and test formulation treated groups. DF1911, DF2112 and DF2813 showed down-regulation of IL1-β (~6.4-fold, ~5.2-fold and ~7.6-fold), IL-6 (~1.1-fold, ~1.6-fold and ~1.9-fold), TNF-α (~2.0-fold, ~4.6-fold and ~3.5-fold), and iNOS (~1.2-fold, ~1.8-fold and ~1.1-fold) in inflamed paw tissue compared to negative control group, respectively. Conclusions The anti-inflammatory effects of DF1911 and DF2112 in rats were significantly higher than the Dashamoola Kwatha and are comparable to Diclofenac sodium

COMPARATIVE FREE RADICAL SCAVENGING AND ANTI-INFLAMMATORY POTENTIAL OF BRANDED MARKET SAMPLES OF AN AYURVEDIC FORMULATION: DASHAMOOLARISHTA

Dashamoolarishta is a well known Ayurvedic Rasayana preparation comprising ten different roots. At least two of these plants are rare, compelling use of alternatives or substitute plant parts, which could results in pharmacological variation in marketed formulations. Moreover, studies on their anti-inflammatory properties are also lacking. This investigation evaluated antioxidant and anti-inflammatory potential of six selected eminent brands of Dashamoolarishta (A, B, C, D, E &amp; F). Sample F stood out as highest (Total Phenolics: 21.67 ± 0.06 mg GAE/g dry mass; ABTS: 29.23 ±0.09 % and Anti Lipid Peroxidation: 91.94 ±0.02 %). Sample E scored lowest in all these values. Formulations F, B and E were further compared using carrageenan-induced rat paw edema model of inflammation. All formulations exhibited variations in anti-inflammatory activity. Maximum inhibition was in animals intervened with formulation F (44.16 %) comparable to that of standard Diclofenac (48.10 %, 10 mg/kg) at 6 h. Our findings support the Ayurvedic rationale of using Dashamoolarishta formulation and its therapeutic use in treatment of inflammatory diseases. It is reiterated that significant variation exists in biochemical and pharmacological potential among marketed formulations